BofA securities starts CureVac (CVAC -10.5%) coverage with buy and sets price target of $70 (23% upside).
Jefferies Financial initiates CureVac with hold, and price target of $58.
Credit Suisse initiates CureVac with neutral and sets PT of $68 (20% upside).
“CureVac has strong development pipeline. The company’s product candidates are in different stages of development. Its lead drug candidate is mRNA based vaccine against COVID-19” writes Avisol Capital Partners on SA.
https://seekingalpha.com/news/3612262-three-analysts-initiate-coverage-on-curevac
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.